drugset / Trial / NCT04723940

Or v IV Antibiotics for Infection

NCT04723940

Phase 3 Unknown 308 enrolled Rothman Institute Orthopaedics
RandomizedParallel-groupOpen-labelTreatment

Summary

Management of periprosthetic joint infection (PJI) commonly includes 6 weeks of intravenous (IV) antibiotics after surgical treatment. However, there is little evidence to suggest that oral (PO) therapy results in worse outcomes. This study aims to determine whether or not PO antibiotics are non-inferior to IV antibiotics in treating PJI. The study is a multicenter, parallel-group, randomized (1 : 1), open-label, non-inferiority trial. The non-inferiority margin will be set at 10%. Adults with a clinical diagnosis of PJI according to the International Consensus Meeting (ICM) criteria who would ordinarily receive at least 6 weeks of antibiotics and have received ≤ 7 days of IV therapy from surgery will be included. A total of 308 participants will be centrally computer-randomized to PO or IV antibiotics to complete the first 6 weeks of therapy. Follow-on PO therapy will be permitted in either arm. The primary outcome is the proportion of participants experiencing treatment failure within 1 year. An associated cost-effectiveness evaluation including complications, resource utilization and quality-of-life data will be performed.

Timeline

Start
2021-01-25
Primary completion
2023-01-25
Completion
2023-01-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cefadroxil Small molecule Intravenous
Comparator Clindamycin Unknown Intravenous
Comparator Doxycycline Small molecule Intravenous
Comparator trimethoprim-sulfamethoxazole Unknown Intravenous